<div>Verge Genomics is a next-generation biopharmaceutical start-up using human genomics to accelerate development of life-saving treatments for neurodegenerative diseases. Our platform uses patient tissue profiling, human genetics, and machine learning to identify new therapeutic gene targets, predict effective drugs, and stratify patient subpopulations for increased clinical success. Verge's approach offers a breakthrough opportunity to identify drugs that dramatically improve patient outcomes and fundamentally lower the cost curve of pharmaceutical development.</div><div><br></div><div>As the Head of Translational Medicine, you will be responsible for developing Verge’s early clinical biomarker strategy and oversee operationalization of biomarker studies in our Phase 1 trials, including the establishment of clinical and analytical lab infrastructure and key relationships. You will also drive the selection of clinical biomarkers for target engagement, patient selection, and signs of efficacy leveraging the unique insights gained from Verge’s genomics platform. The Head of Translational Medicine will also interface with the preclinical discovery teams to help drive efforts related to novel biomarker discovery using Verge's industry-leading multi dimensional discovery platform and ensure a comprehensive biomarker strategy is implemented for all preclinical discovery programs.</div>